Peroxisome proliferator-activated receptor-χ ligands as bone turnover modulators

Expert Opinion on Investigational Drugs

Volumn 16, Issue 2, 2007, Pages 195-207

  Giaginis, Costas ^a   Tsantili Kakoulidou, Anna ^a   Theocharis, Stamatios ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bone formation; Bone resorption; Osteoporosis; PRAR ligand

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 BROMOPALMITIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 9 HYDROXYOCTADECADIENOIC ACID; 9,10 DIHYDROXYOCTADECENOIC ACID; 9,10 EPOXYOCTADECENOIC ACID; ALKALINE PHOSPHATASE; CIGLITAZONE; DARGLITAZONE; NETOGLITAZONE; OSTEOCALCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PROCOLLAGEN; REGLITAZAR; ROSIGLITAZONE; TRANSCRIPTION FACTOR RUNX2; TROGLITAZONE; UNCLASSIFIED DRUG;

AGING; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE CELL; BONE DISEASE; BONE TISSUE; BONE TURNOVER; CELL DIFFERENTIATION; CELL MATURATION; DISEASE ASSOCIATION; HUMAN; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PROTEIN EXPRESSION; REVIEW;

ANIMALS; BONE DISEASES; BONE REMODELING; DRUGS, INVESTIGATIONAL; HUMANS; LIGANDS; OSTEOGENESIS; PPAR GAMMA;

EID: 33846826953     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.2.195     Document Type: Review

References (92)

1. NOLTE RT, WISELY GB, WESTIN S et al.: Ligand binding and co-activator assembly of the peroxisome proliferators; activated receptor-γ. Nature (1998) 395:137-143.
2. VIDAL-PUIG AJ, CONSIDINE RV, JIMENEZ M et al.: Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. (1997) 99:2416-2422.
3. KLIEWER SA, FORMAN BM, BLUMBERG B et al.: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA (1994) 91:7355-7359.
4. RIZZO G, FIORUCCI S: PPARs and other nuclear receptors in inflammation. Curr. Opin. Pharm. (2006) 6:1-7.
5. BRAISSANT O, FOUFELLE F, SCOTTO C, DAUÇA M, WAHLI W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, β- and -γ in the adult rat. Endocrinology (1996) 137:354-366.
6. FAJAS L, AUBOEUF D, RASPE E et al.: The organization, promoter analysis and expression of the human PPARγ gene. J. Biol. Chem. (1997) 272:18779-18789.
7. WILLSON TM, BROWN PJ, STRENBACH DD, HENKE BR: The PPARs: from orphan receptors to drug discovery. J. Med. Chem. (2000) 43:527-550.
8. BERGER J, MOLLER DE: The mechanisms of action of PPARs. Ann. Rev. Med. (2002) 53:409-435.
9. GEARING KL, GOTTLICHER M, TEBOUL M, WIDMARK E, GUSTAFSSON JA: Interaction of the peroxisome proliferator-activated receptor and retinoid X receptor. Proc. Natl. Acad. Sci. USA (1993) 90:1440-1444.
10. FEIGE JN, GELMAN L, MICHALIK L, DESVERGNE B, WAHLI W: From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog. Lipid Res. (2006) 45:120-159.
11. TOLON RM, CASTILLO AI, ARANDA A: Activation of the prolactin protein gene by peroxisome proliferator-activated receptor-α appears to be DNA binding-independent. J Biol. Chem. (1998) 273:26652-26661.
12. RICOTE M, LI AC, WILLSON TM, KELLY CJ, GLASS CK: The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature (1998) 391:79-82.
13. FEINSTEIN DL, SPANGOLO, A, AKAR C et al.: Receptor-independent actions of PPAR thiazolidinedione agonists: is a mitochondrial function the key? Biochem. Pharm. (2005) 70:177-188.
14. THEOCHARIS S, MARGELI A, VIELH P, KOURAKLIS G: Peroxisome proliferator-activated receptor-γ ligands as cell-cycle modulators. Cancer Treat. Rev. (2004) 30:545-554.
15. THEOCHARIS S, MARGELI A, KOURAKLIS G: Peroxisome proliferator activated receptor-γ ligands as potent antineoplastic agents. Curr. Med. Chem. Anticancer Agents (2003) 3:239-251.
16. MARGELI A, KOURAKLIS G, THEOCHARIS S: Peroxisome proliferator activated receptor-γ (PPAR-γ) ligands and angiogenesis. Angiogenesis (2003) 6:165-169.
17. HAMERMAN D: Osteoporosis and atheroslerosis: biological linkages and the emergence of dual-purpose therapies. Q. J. Med. (2005) 98:467-484.
18. PERSHADSINGH HA: Peroxisome proliferator-activated receptor-γ: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin. Investig. Drugs (2004) 13(3):215-228.
19. TENENBAUM A, MOTRO M, FISMAN EZ: Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cordiovasc. Diabetol. (2005) 4:14.
20. KARSENTY G, WAGNER EF: Reaching a genetic and molecular understanding of skeletal development. Develop. Cell (2002) 2:389-406.
21. MANOLAGAS SC: Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. (2000) 21:115-137.
22. HARADA S, RODAN GA: Control of osteoblast function and regulation of bone mass. Nature (2003) 423:349-355.
23. PIEPKORN B, KANN P, FORST T, ANDREAS J, PFUTZNER A, BEYER J: Bone mineral density and bone metabolism in diabetes mellitus. Horm. Metab. Res. (1997) 29:584-591.
24. AKUNE T, OHBA S, KAMEKURA S et al.: PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J. Clin. Invest. (2004) 113:846-855.
25. hyp/hyp mice relocates haematopoiesis to the spleen. EMBO Rep. (2004) 5:1007-1012.
26. OGAWA S, URANO T, HOSOI T et al.: Association of bone mineral density with polymorphism of the peroxisome proliferator-activated receptor γ gene: PPARγ expression in osteoblasts. Biochem. Biophys. Res. Commun. (1999) 260:122-126.
27. RHEE E-J, OH K-W, LEE W-Y et al.: The effect of C 161 →T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-γ gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. Am. J. Obstet. Gynecol. (2005) 192:1087-1093.
28. CECCHINI MG, PORTENIER J, WETTERWALD A, BRAISSANT O, WAHLI W: Expression of peroxisome proliferator activated receptors in rat bone. J. Bone Miner. Res. (1997) 12:S458.
29. SHAO YY, WANG L, HICKS DG, TARR S, BALLOCK RT: Exression and activation of peroxisome proliferator-activated receptors in growth plate chondrocytes. J. Orthop. Res. (2005) 23:1139-1145.
30. GIMBLE JM, ZVONIC S, FLOYD ZE, KASSEM M, NUTTALL ME: Playing with fat and bone. J. Cell. Biochem. (2006) 98:251-266.
31. ALI AA, WEINSTEIN RS, STEWART SA, PARFITT AM, MANOLAGAS SC, JILKA RL: Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology (2005) 146:1226-1235.
32. KAWAGUCHI H, AKUNE T, YAMAGUCHI M et al.: Distinct effects of PPARγ insufficiency on bone marrow cells, osteoblasts, and osteoclastic cells. J. Bone Miner. Metab. (2006) 23:275-279.
33. SCHMIDT A, ENDO N, RUTLEDGE SJ, VOGEL R, SHINAR D, RODAN GA: Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol. Endocrinol, (1992) 6:1634-1641.
34. DIASCRO DD, VOGEL RL, JOHNSON TE et al. High fatty acid content in rabbit serum is responsible for the differentiation of osteoblasts into adipocyte-like cells. J. Bone Miner. Res. (1998) 13:96-106.
35. HAYDON RC, ZHOU L, FENG T et al.: Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin. Cancer Res. (2002) 8:1288-1294.
36. BORDJI K, GRILLASCA JP, GOUZE JN et al.: Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) α and γ and retinoid z receptor in cartilage. PPARβ activation modulates the effects of interleukin- 1β on rat chondrocytes. J. Biol Chem. (2000) 275:12243-12250.
37. 2, but not troglitazone, modulates IL- 1β effects in human chondrocytes by inhibiting NF-κB and AP-1 activation pathways. FEBS Lett. (2001) 501:24-30.
38. FAHMI H, DI BATTISTA JA, PELLETIER J-P, MINEAU F, RANGER P, MARTEL-PELLETIER J: Peroxisome proliferator-activated receptor γ activators inhibit interleukin-1β and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum. (2001) 44:595-607.
39. 2 for induction of human articular chondrocytes apoptosis in arthritis. J. Biol. Cbem. (2004) 279:37939-37950.
40. NISHIDA K, FURUMATSU T, TAKADA I et al.: Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor-γ. Br. J. Cancer (2002) 86:1303-1309.
41. 2. Biochem. Biophys. Res. Commun. (1996) 224:431-437.
42. AKBIYIK F, RAY DM, GETTINGS KF, BLUMBERG N, FRANCIS CW, PHIPPS RP: Human bone marrow megakaryocytes and platelets express PPARγ, and PPARγ agonists blunt platelet release of CD40 ligand mid thromboxanes. Blood (2004) 10:1361-1368.
43. KACENA MA, GUNDBER CM, HOROWITZ MC: A reciprocal regulatory interaction between megakaryokytes, bone cells and hematopoietic stem cells. Bone (2006) 39:978-984.
44. MAURIN AC, CHAVASSIEUX PM, MEUNIER PJ: Expression of PPARγ and β/δ in human primary osteoblastic cells: influence of polyunsaturated fatty acids. Calcif. Tissue Int. (2005) 76:385-392.
45. GREENE ME, BLUMBERG B, McBRIDE OW et al.: Isolation of human peroxisome proliferator-activated receptor γ cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Exp. (1995) 4:281-299.
46. JACKSON SM, DEMER LL: Peroxisome proliferators-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preoblasts. FEBS Lett. (2000) 471:119-124.
47. JEON MJ, KIM JA, KWON SH et al.: Activation of peroxisome proliferator-activated receptor-γ inhibits the Runx2-mediated transcription of osteocalsin in osteoblasts. J. Biol. Chem. (2003) 278:23270-23277.
48. 1. Proc. Natl. Acad. Sci. USA (2001) 98:2443-2448.
49. SHEVDE NK, BENDIXEN AC, DIENGER KM, PIKE JW. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc. Natl. Acad. Sci. USA (2000) 97:7829-7834.
50. GIMBLE JM, ROBINSON CE, WU X et al: Peroxisome proliferator-activated receptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol. Pharmacol. (1996) 50:1087-1094.
51. MOERMAN EJ, TENG K, LIPSCHITZ DA, LECKA-CZERNIK B: Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-γ2 transcription factor and TGF-β/ BMP signaling pathways. Aging Cell (2004) 3:379-389.
52. 2. J. Cell. Biochem. (1999) 74:357-371.
53. 2 ligands on adipocyte versus osteoblast differentiation, Endocrinology (2002) 143:2376-2384.
54. OKAZAKI R, TORIUMI M, FUKUMOTO S et al.: Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology (1999) 140:5060-5065.
55. RZONCA SO, SUVA LJ, GADDY D, MONTAGUE DC, LECKA-CZERNIK B: Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology (2004) 145:401-406.
56. SOTTILE V, SEUWEN K, KNEISSEL M: Enhanced marrow adipogenesis an bone resorption in estrogen-derived rats treated with the PPARγ agonist BRL4963 (rosiglitazone). Calcif, Tissue Int. (2004) 75:329-337.
57. SOROCEANU MA, MIAO D, BAI X-Y, SU H, GOLTZMAN D, KARAPLIS AC: Rosiglitazone impacts negatively on bone by promoting osteoblast/ osteocyte apoptosis. J. Endocrinol. (2004) 183:203-216.
58. NUTTALL ME, PATTON AJ, OLIVERA DL, NADEAU DP, GOWEN M: Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorder. J. Bone Miner. Res. (1998) 13:371-382.
59. JENNERMANN C, TRIANTAFILLOU J, COWAN D, PENNINK BGA, CONNOLLY KM, MORRIS DC: Effects of thiazolidinediones on bone turnover in the rat. J. Bone Miner. Res. (1995) 10:S241.
60. TORNVIG L, MOSEKILDE LI, JUSTESEN J, FALK E, KASSEM M: Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif. Tissue Int. (2001) 69:46-50.
61. SALAMONE LM, GAULEY JA, ZMUDA J et al.: Apolipoprotein E gene polymorphism and bone loss: estrogen status modifies the influence of apolipoprotein E on bone loss. J. Bone Miner. Res. (2000) 15:308-314.
62. SHIBITA T, TAKEUCHI S, YOKOTA S, KAKIMOTO K, YONEMORI F, WAKITANI K: Effects of peroxisome proliferator-activated receptor-α and -γ agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. Br. J. Pharmacol. (2000) 130:495-504.
63. YASUDA E, TOKUDA H, ISHISAKI A et al.: PPARγ ligands up-regulate basic fibroblast growth factor-induced VEGF release through amplifying SAPK/ JNK activation in osteoblasts. Biochem. Biophys. Res. Common. (2005) 328:137-143.
64. GERBER HP, VU TH, RYAN AM, KOWALSKI J, WERB Z, FERRARA N: VEGF couples hypertrophic cartilage remodelling, ossification and angiogenesis during endochondral bone formation. Nat. Med. (1999) 5:623-628.
65. LAZARENKO OP, RZONCA SO, SUVA LJ, LECKA-CZERNICK B: Netoglitazone is a PPAR-γ ligand with selective effects on bone and fat. Bone (2006) 38:74-84.
66. JOHNSON TM, VOGEL R, RUTLEDGE SJ, RODAN G, SCHMIDT A: Thiazolidinedione effects on glucocorticoid receptor-mediated gene transcription and differentiation in osteoblastic cells. Endocrinology (1999) 140:3245-3254.
67. LI M, PAN LC, SIMMONS HA, LI Y et al.: Surface-specific effects of a PPARγ agonist, dargiltazone, on bone in mice. Bone (2006) 39:796-806.
68. KHAN E, ABU-AMER Y. Activation of peroxisome proliferator-activated receptor-γ inhibits differentiation of preosteoblasts. J. Lab. Clin. Med. (2003) 142:29-34.
69. 1 derivative TEI-3313.J. Pharmacol. Exp. Ther. (1991) 258:1120-1126.
70. 2 metabolite stimulates collagen synthesis by human osteoblasts during calcification. Prostaglandins (1991) 41:301-313.
71. 1 derivative, prevents bone loss and enhances bone formation in immobilized male rats. J. Pharmacol. Exp. Ther. (1995) 275:450-455.
72. PARHAMI F, JACKSON SM, TINTUT T et al.: Atherogenic diet and minimally oxidized low density lipoprotein inhibit osteogenic and promote adipogenic differentiation of marrow stronial cells. J. Bone Miner. Res. (1999) 14:2067-2078.
73. PARHAMI F, TINTUT Y, BEAMER WG, GHARAVI N, GOODMAN W, DEMER LL: Atherogenic high-fat diet reduces bone mineralization in mice. J. Bone Miner. Res. (2001) 16:182-188.
74. VON DER RECKE P, HANSEN MA, HASSAGER C: The association between low bone mass at the menopause and cardiovasular mortality. Am. J. Med. (1999) 106:273-278.
75. MBALAVIELE G, ABU-AMER Y, MENG A et al.: Activation of peroxisome proliferator-activated receptor-γ pathway inhibits oosteoclast differentiation. J. Biol. Chem. (2000) 275:14388-14393.
76. SAKAGUCHI K, MORITA I, MUROTA S: Relationship between the ability to support differentiation of osteoclast-like cells and adipogenesis in murine stromal cells derived from bone marrow. Prostangladins Leukot. Essent. Fatty Acids (2000) 62:319-327.
77. TOMITA T, KOKIUCHI Y, TSAO PS: THR0921, a novel peroxisome proliferator-activated receptor γ agonist, reduces the severity of collagen-induced arthritis. Arthritis Res. Ther. (2005) 8:R7.
78. KELLY KA, TANAKA S, BARON R, GIMBLE JM: Murine bone marrow stromally derived BMS2 adipocytes support differentiation and function of osteoclast-like cells in vitro. Endocrinology (1998) 139:2092-2101.
79. SCHWAB AM, GRANHOLM S, PERSSON E, WILKES B, LERNER UH, CONAWAY HH: Stimulation of resorption in cultured mouse calvarial bones by thiazolidinediones. Endocrinology (2005) 145:4349-4361.
80. GIAGINIS C, THEOCHARIS S, TSANTILI-KAKOULIDOU A: Investigation of the lipophilic behavior of the PPAR-γ ligands thiazolidinediones as an important issue for their action. Drugs Future (2006) 31:A44.
81. HONG JH, HWANG ES, McMANUS MT et al.: TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science (2005) 309:1074-1078.
82. SCHWARTZ AV, SELLMEYER DE, FEINGOLD KR et al.: Thiazolidinediones (TZD) use and bone density in older adults with diabetes. Diabetes (2002) 51:A237.
83. SCHWARTZ AV, SELLMEYER DE, VITTING HOFF E et al.: Thiazolidinediones (TZD) use and bone density in older adults with diabetes. J. Clin. Endocrinol. Metab. (2006) 91:3349-3354.
84. OKAZAKI R, MIURA M, TORIUMI M et al.: Short-term treatment with troglitazone decreases bone turnover in patients with Type 2 diabetes mellitus. Endocr.J. (1999) 46:795-801.
85. WATANABE S, TAKEUCHI Y, FUKUMOTO S et al.: Decrease in serum leptin by troglitazone is associated with preventing bone loss in Type 2 diabetic patients. J. Bone Miner. Metab. (2003) 21:166-171.
86. VAN DAELE PLA, STOLK RP, BURGER H et al.: Bone density in non-insulin-dependent diabetes mellitus: the Rotterdam study. Ann. Intern. Med. (1995) 122:409-414.
87. WAKASUGI M, WAKAO R, TAWATA M, GAN N, KOIZUMI K, ONAYA T: Bone mineral density measured by dual energy Xray absorptiometry in patients with non-insulin-dependent diabetes mellitus. Bone (1993) 14:29-33.
88. WEINSTOCK RS, GOLAND RS, SHANE E, CLEMENS TL, LINDSAY R, BILEZIKIAN JP: Bone mineral density in women Type II diabetes mellitus. J. Bone Miner. Res. (1989) 4:97-101.
89. KIM SH, YOO CI, KIM HT, PARK JY, KWON CH, KIM YK: Activation of peroxisome proliferator-activated receptor-γ (PPARγ) induces cell death through MAPK-dependent mechanism in osteoblastic cells. Toxicol. Appl. Pharmacol. (2006) 215:198-207.
90. LUCARELLI E, SANGIORGI L, MAINI V et al.: Troglitazone affects survival of human osteosarcoma cells. Int. J. Cancer (2002) 98:344-351.
91. 2 is associated with altered expression of Bax/Bcl-xL and p21. Biochem. Biophys. Res. Commun. (2005) 328:375-382.
92. MAURIN AC, CHAVASSIEUX PM, VERICEL E, MEUNIER PJ: Role of polyunsaturated fatty acids in the inhibitory effect of human adipocytes on osteoblastic proliferation. Bone (2002) 31:260-266.